Ajanta Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Ajanta Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 3125, up 1.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.38% on the day, quoting at 23468.45. The Sensex is at 74886.66, up 0.44%. Ajanta Pharma Ltd has added around 8.39% in last one month.

Meanwhile, Nifty Pharma index of which Ajanta Pharma Ltd is a constituent, has added around 6.63% in last one month and is currently quoting at 23840.9, up 0.34% on the day. The volume in the stock stood at 1.49 lakh shares today, compared to the daily average of 1.24 lakh shares in last one month.

The PE of the stock is 40.79 based on TTM earnings ending March 26.

Powered by Capital Market - Live News

The domestic equity benchmarks traded with moderate gains in morning trade, buoyed by optimism over a potential US?Iran peace deal. Softer geopolitical tensions pushed Brent below $110 per barrel, while the rupee strengthened to hover near the 95-per-dollar mark. However, investors remain focused on Q4 earnings for near-term cues. The Nifty hovered above the 24,150 mark.

Auto shares witnessed buying demand for third consecutive trading session.

At 10:25 IST, the barometer index, the S&P BSE Sensex added 305.52 points or 0.40% to 77,323.31. The Nifty 50 index jumped 113.70 points or 0.47% to 24,144.30.

The broader market outperformed the frontline indices. The BSE 150 MidCap Index rose 0.98% and the BSE 250 SmallCap Index dropped 0.68%.

The market breadth was strong. On the BSE, 2,405 shares rose and 1,252 shares fell. A total of 201 shares were unchanged.

The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, declined 2.73% to 17.42.

In the commodities market, Brent crude for June 2026 settlement declined $1.89 or 1.72% to $107.98 a barrel.

In the foreign exchange market, the rupee edged higher against the dollar. The partially convertible rupee was hovering at 95.075 compared with its close of 95.1800 during the previous trading session.

Earnings Today:

Bajaj Auto(up 1.77%), CG Power and Industrial Solutions(down 0.91%), Polycab India(up 0.96%), Godrej Consumer Products(down 0.11%), Meesho(down 4.11%), Shree Cements(up 0.64%), PB Fintech(down 0.13%), One 97 Communications(up 0.85%), Radico Khaitan(up 1.16%), Blue Star(down 1.46%), Hexaware Technologies(up 0.56%), KPIT Technologies(up 2.03%), Brigade Enterprises(up 1.07%), Aditya Birla Real Estate (up 0.57%), Kansai Nerolac Paints(down 0.12%), Firstsource Solutions(up 0.70%), Birlasoft(up 1.70%), KPI Green Energy(up 1.10%), Avalon Technologies(down 1.27%), Arvind Fashions(up 3.51%), Raymond Lifestyle(up 2.77%), Sula Vineyards(up 1.47%), PNGS Gargi Fashion Jewellery will declare their results later today.

Buzzing Index:

The Nifty Auto index jumped 1.75% to 26,649.95. The index rose 2.83% in the three consecutive trading sessions.

Mahindra & Mahindra (up 2.93%), Hero MotoCorp (up 2.68%), Samvardhana Motherson International (up 2.38%), Ashok Leyland (up 1.7%), Tata Motors Passenger Vehicles (up 1.68%), Bajaj Auto (up 1.63%), Bharat Forge (up 1.49%), Maruti Suzuki India (up 1.07%), TVS Motor Company (up 0.85%) and Bosch (up 0.52%) avanced.

Stocks in Spotlight:

Ajanta Pharma rose 2.43% after the pharmaceutical company reported healthy Q4 FY26 earnings, driven by steady performance across branded markets. On a consolidated basis, net profit rose 18.4% YoY but declined 2.6% QoQ to Rs 266.70 crore in Q4 FY26. Revenue from operations stood at Rs 1,421.64 crore in Q4 FY26, up 21.5% YoY and 3.4% QoQ.

Larsen & Toubro (L&T) declined 3.13% after the company reported a 3.12% decline in consolidated net profit to Rs 5,325.60 crore, despite a 11.25% increase in revenue from operations to Rs 82,762.16 crore in Q4 FY26 over Q4 FY25.

Powered by Capital Market - Live News

On a consolidated basis, net profit rose 18.4% YoY but declined 2.6% QoQ to Rs 266.70 crore in Q4 FY26. Revenue from operations stood at Rs 1,421.64 crore in Q4 FY26, up 21.5% YoY and 3.4% QoQ.

EBITDA stood at Rs 333 crore in Q4 FY26, up 12% YoY from Rs 297 crore in Q4 FY25. EBITDA margin came in at 23%. The company said mark-to-market forex loss stood at Rs 42 crore during the quarter. Excluding this impact, EBITDA stood at Rs 375 crore, reflecting 26% growth with EBITDA margin at 26%.

Profit before tax stood at Rs 347.11 crore in Q4 FY26, down 3.2% vs Q3 and up 28.8% vs Q4 FY25.

Employee benefits expense rose 21.8% YoY to Rs 340.72 crore in Q4 FY26 from Rs 279.78 crore in Q4 FY25, while other expenses increased 42.8% YoY to Rs 442.70 crore from Rs 310.06 crore a year earlier. Finance costs declined 61.1% YoY to Rs 2.36 crore from Rs 6.07 crore in the corresponding quarter last year.

On the operational front, the company?s US generics business delivered strong momentum, with Q4 revenue surging 56% YoY to Rs 505 crore. For the full year, the segment grew 49% to Rs 1,557 crore.

Within branded generics, India business revenue increased 9% YoY to Rs 404 crore during the quarter, while Africa business climbed 37% YoY to Rs 182 crore. Asia business, however, declined 10% YoY to Rs 274 crore.

For FY26, Ajanta Pharma reported revenue from operations of Rs 5,452.86 crore, up 17% YoY, while PAT rose 14.7% to Rs 1,056 crore. EBITDA for the year stood at Rs 1,395 crore, up 11% YoY with EBITDA margin at 26%.

The company said return on capital employed stood at 33% while return on net worth came in at 25% during FY26.

Ajanta Pharma is a speciality pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa.

Powered by Capital Market - Live News

Net profit of Ajanta Pharma rose 18.40% to Rs 266.70 crore in the quarter ended March 2026 as against Rs 225.26 crore during the previous quarter ended March 2025. Sales rose 21.47% to Rs 1421.64 crore in the quarter ended March 2026 as against Rs 1170.41 crore during the previous quarter ended March 2025.

For the full year,net profit rose 14.73% to Rs 1056.00 crore in the year ended March 2026 as against Rs 920.39 crore during the previous year ended March 2025. Sales rose 17.31% to Rs 5452.86 crore in the year ended March 2026 as against Rs 4648.10 crore during the previous year ended March 2025.

Powered by Capital Market - Live News